A separate retrospective study of 27 melanoma patients who received infliximab for the treatment of immune-related colitis (with PDl-1 and/or CTLA-4 inhibitors) showed that cancer outcomes were not affected (45). This evidence concerns the gene CTLA4 and cancer.